What Happens to Your Warrants at Series B: Why Legacy Warrant Overhang Kills Institutional Deals Quietly

A warrant is a contractual right to purchase shares at a fixed price, usually issued outside a formal equity plan, to a lender, bridge investor, service provider, or advisor. Unlike employee stock options, warrants are standalone agreements. They do not live inside your option pool. They do not follow the same documentation standards. And they do not disappear when you stop thinking about them.

At Series B, a lead investor models your fully diluted ownership before they evaluate your deck. When warrants surface in that model without clear documentation, disclosed anti-dilution terms, and resolved lender-consent obligations, the investor faces three questions they cannot answer from your data room. What is the true diluted share count? Do any warrants reprice automatically when the round closes? And does any lender hold consent rights that must be cleared before equity can be issued?

A lead who cannot answer those questions does not negotiate around the uncertainty. They reprice or walk.

The full picture of what kills a Series B before diligence begins is covered in the complete guide to cap table issues that block institutional financing. This article focuses specifically on warrant mechanics and what founders must resolve before approaching a lead.

Key takeaways:

• Warrants issued to lenders, bridge investors, advisors, and service providers are contractual rights, not equity plan grants, and they carry terms that options do not
• Outstanding warrants expand fully diluted share count and can reprice automatically when a Series B closes
• Cashless exercise provisions make the final net-share count unknowable until the closing price is fixed
• Venture debt warrants often sit inside a broader loan agreement that includes lender consent rights over new equity issuances
• Undisclosed or poorly modeled warrant overhang is read as a disclosure failure, not a clerical gap
• Founders must build a complete warrant register, model dilution at the proposed round price, and assess every consent and anti-dilution term before outreach begins

What Warrants Actually Are and Why Founders Issue Them

Warrants get issued in four common situations before a Series B. Each type creates different diligence exposure.

Venture debt warrants are the most structurally significant. Banks typically ask for coverage of 1-2% of the loan principal, while specialized venture debt funds may request 2-5% or more, depending on risk and deal terms. A $5M venture debt facility with 2% coverage produces warrants for $100,000 worth of equity at the strike price, which is usually set at the most recent preferred round's price per share.

The reason warrants end up outside formal equity-plan hygiene is straightforward. They are negotiated as part of a debt or service agreement, not as a compensation grant. No board approval process exists for them in the same way it does for option grants. They get filed with the loan documents and then sit there, quietly accumulating, while the cap table is maintained as if they do not exist. Cooley GO's warrant reference guide for founders notes that warrant terms between 2 and 10 years are standard, which means instruments issued at seed stage can still be outstanding and unmodeled when a Series B lead opens the data room.

That is the first problem a Series B lead finds.

Why Warrants Create Series B Valuation Problems

Three specific mechanics turn warrant overhang into a valuation problem at Series B.

1. Warrants expand the fully diluted share count

Every outstanding warrant is a potential share. A lead investor building a fully diluted ownership model includes all warrants, whether exercised or not, because they represent future dilution that affects the economic value of the round. If your cap table shows 10 million shares outstanding but you have 500,000 warrants outstanding that were never added to the model, the lead's ownership percentage is different from what you presented.

2. Anti-dilution and price adjustment provisions can reprice at closing

Some warrant agreements include broad-based weighted average or full-ratchet anti-dilution provisions. When the Series B closes at a price per share that triggers the adjustment formula, those warrants reprice automatically. The result is a larger share count than the face warrant register shows, and founders often discover this only when counsel reviews the warrant agreement during diligence.

3. Cashless exercise makes the final share count unknowable until closing

A cashless exercise provision lets the holder convert the warrant into shares without paying the exercise price in cash. The net-share settlement formula typically produces fewer shares than a cash exercise would, but the exact number depends on the fair market value of the stock at the time of exercise. Until the Series B price is fixed, that number cannot be calculated.

These three problems compound when they appear together, which they often do. Wilson Sonsini's private company financing data shows warrants appearing in 15-22% of post-seed convertible note deals in recent years, meaning a meaningful share of founders approaching Series B carry warrant obligations that were never modeled against a priced round. The Wilson Sonsini Entrepreneurs Report tracks these terms across hundreds of transactions annually.

Why Warrants Create Governance and Lender-Consent Problems

Dilution is visible in the numbers. Governance risk is buried in the agreements. Both matter, but governance problems are harder to fix quickly under live diligence pressure.

Under Delaware law, warrant holders are not stockholders. They do not have voting rights, information rights, or other stockholder protections until they exercise their warrants and receive shares. Delaware General Corporation Law Section 157 governs the issuance of rights and options respecting stock, and the Delaware Court of Chancery has confirmed that warrant holders are not owed fiduciary duties and there is no general duty to keep them informed about corporate plans. However, warrant agreements are contracts, and those contracts can contain rights that create real friction in a financing.

The most common governance and consent issues found in warrant agreements include:

• Lender consent clauses. Venture debt warrant agreements are often part of a broader loan package that includes negative covenants restricting the company from issuing new equity, modifying the cap table, or closing a financing without lender approval. That consent requirement applies to the Series B closing, not just the warrants themselves.
• Notice requirements. Some warrant agreements require the company to give the holder advance notice before a financing, merger, or other material event. A missed notice period can create a claim that the holder's contractual rights were violated.
• Information rights. Side-letter style information rights attached to a warrant agreement can conflict with the confidentiality obligations of a live Series B process.
• Modification restrictions. Some warrant agreements restrict the company from amending the cap table or issuing shares in ways that would affect the warrant's exercise price or share coverage without holder consent.

Investor takeaway: When a Series B lead finds a warrant agreement with lender consent requirements that were never disclosed, the question is not whether the consent can be obtained. The question is why the company did not disclose it before the process started. That is a disclosure-control failure, and it changes how the lead reads everything else in the data room.

Understanding how debt and equity instruments interact across a capital structure is essential context for any founder who has used venture debt before approaching a Series B.

What Must Be Resolved Before Approaching a Series B Lead

Founders who have issued warrants at any point before their Series B need to complete four steps before the first investor conversation. These are not diligence responses. They are pre-market requirements.

Step 1: Build a complete warrant register

Every outstanding warrant needs to be documented in a single register that includes: holder name, grant date, exercise price, number of shares covered, expiration date, anti-dilution provisions (if any), cashless exercise mechanics (if applicable), and a reference to the governing agreement. If a warrant expired without exercise, confirm that in writing. If a warrant was cancelled, confirm that too. The register should reconcile against signed agreements, not just cap table software.

Step 2: Model fully diluted ownership at the proposed Series B price

Take the proposed round price and run the diluted model. Include every warrant on a cash-exercise basis and, separately, on a cashless-exercise basis using the net-share formula in each agreement. If any warrant has an anti-dilution clause, model what the adjusted share count looks like at the Series B price. The difference between your current cap table and the fully diluted model at close is what the lead investor will see. You need to see it first.

Step 3: Review every agreement for consent and conflict terms

Pull the governing document for each warrant. Review it for: lender consent requirements before equity issuances, notice periods, information rights, and any term that conflicts with the Series B preferred stock protections or the proposed investor rights agreement. Counsel should review this, not just the finance team.

Step 4: Decide on the cleanest path before outreach

Once you have the register, the model, and the consent review, you can make an informed decision: carry the warrants through the round with full disclosure and a clean model, negotiate pre-close cancellation or buyout with the holder, or facilitate a pre-close cashless exercise that converts the warrant into a known, fixed share count before diligence begins.

The founders who retain the most leverage are the ones who have already made this decision before the first term sheet conversation.

The same modeling discipline that applies to how stacked SAFEs affect your Series B cap table applies here. The lead investor will build this model. Build it first.

When Cancellation or Cashless Exercise Is the Right Answer, and When Disclosure Is Enough

Not every warrant needs to be cancelled or exercised before a Series B. The right answer depends on the specific terms, the holder relationship, and what creates the cleaner path to close.

Decision principle: The question is not whether the company can technically carry the warrant through the round. The question is whether the warrant becomes easier to underwrite after the fix. If the answer is yes, fix it. If the answer is no, a clean model and complete disclosure may be sufficient.

Cancellation or buyout is usually the right path when:

• The holder is a current lender or service provider who can be approached for consent without disrupting the relationship
• The warrant agreement contains lender consent, notice, or information rights that would create friction during the Series B process
• The anti-dilution provisions in the agreement would trigger repricing at the Series B close
• The economic value of the warrant to the holder is small enough that a negotiated cancellation payment is straightforward

Pre-close cashless exercise works when:

• The exercise price is low relative to the current stock price, producing a small and predictable net-share count
• The cashless exercise formula in the agreement is simple and deterministic
• The resulting share issuance is immaterial relative to fully diluted shares outstanding
• No lender consent or anti-dilution issues survive the exercise

Disclosure and modeling may be sufficient when:

• The warrant count is small relative to fully diluted shares and the dilution impact is immaterial
• The documentation is complete, signed, and consistent with the cap table record
• No consent, notice, or anti-dilution provisions exist that would interact with the Series B closing
• The holder has no information rights or other contractual terms that conflict with the financing

The mechanics of how convertible notes and SAFEs create similar disclosure and modeling obligations at Series B are covered in detail in the companion article on seed-stage instrument overhang.

Pre-Series B Warrant Cleanup Checklist

Use this checklist with your legal counsel and finance team at least 90 days before outreach begins.

• Inventory every outstanding warrant against signed governing agreements and cap table records
• Confirm exercise price, expiration date, and share count for each warrant
• Identify any warrants with anti-dilution, price adjustment, or cashless exercise provisions
• Pull the full debt package for every venture loan associated with a warrant and review for financing consent requirements
• Review all side letters, advisory agreements, and service contracts for warrant-related rights
• Model fully diluted ownership at the proposed Series B price under both cash and cashless exercise scenarios
• Assess whether cancellation, buyout, pre-close exercise, or disclosure is the cleanest path for each outstanding warrant
• Prepare a one-page warrant summary memo for the data room that gives the lead investor a complete picture before diligence questions begin

Before approaching a Series B lead: build a complete warrant register, model the fully diluted share count at the proposed round price including all anti-dilution adjustments, review every warrant agreement for lender consent requirements, and assess whether cancellation or cashless exercise before closing is cleaner than disclosure alone. A Series B lead who finds undisclosed warrants with lender consent requirements mid-diligence does not negotiate around them. They reprice or walk.

Frequently Asked Questions

Do outstanding warrants count toward fully diluted shares at Series B?

Yes. All outstanding warrants are included in the fully diluted share count regardless of whether they have been exercised. A lead investor models fully diluted ownership using the treasury stock method or a simple outstanding-share total that includes every warrant, vested option, and convertible instrument. Warrants that are out of the money may be excluded from some dilution models, but in-the-money warrants are always included.

How do anti-dilution provisions in a warrant interact with a Series B priced round?

A warrant with a broad-based weighted average anti-dilution provision will reprice automatically when the Series B closes at a price per share below the warrant's original exercise price. That repricing increases the number of shares the holder can purchase at the adjusted price, creating additional dilution beyond what the face warrant register shows. Full-ratchet provisions are more aggressive and reprice the warrant to the new round price directly. Both must be modeled before the round is priced.

Do venture lender warrants require consent before a Series B financing can close?

It depends on the loan agreement, not the warrant agreement alone. Many venture debt facilities include negative covenants that restrict the company from issuing new equity or closing a financing without lender consent. That consent right lives in the loan agreement and applies to the Series B regardless of the warrant. Founders should review the full loan package with counsel, not just the warrant certificate.

What is cashless exercise and how does it affect the share count at closing?

Cashless exercise lets a warrant holder receive shares without paying the exercise price in cash. The number of shares issued is calculated using a net-share formula: shares issued equals the warrant's in-the-money value divided by the current fair market value. Because the formula depends on the stock price at the time of exercise, the exact share count cannot be determined until the Series B closing price is set. A $100,000 in-the-money warrant at a $20 stock price produces 5,000 shares. At a $25 price, the same warrant produces only 4,000 shares.

How should warrants be disclosed in a Series B data room?

Prepare a warrant summary table that lists every outstanding warrant with holder name, grant date, exercise price, share count, expiration date, anti-dilution terms, cashless exercise provisions, and a link to the governing agreement. Include a separate column showing the fully diluted share count impact under both cash and cashless exercise scenarios at the proposed round price. The lead investor should be able to underwrite the warrant overhang from a single document without requesting follow-up materials.

Can warrants be cancelled before a Series B closes?

Yes. Warrant cancellation requires the holder's written consent and is typically documented through a warrant cancellation agreement signed by both parties. The company may offer a small cash payment or equity consideration in exchange for cancellation, particularly when the warrant is in the money. Cancellation eliminates the warrant from the cap table entirely and removes any associated consent, anti-dilution, or information rights. Counsel should confirm that the cancellation agreement releases all claims under the original warrant agreement.

What happens to expired warrants on the cap table?

An expired warrant has no legal effect. The holder's right to purchase shares terminates on the expiration date stated in the agreement. However, expired warrants should still be confirmed in writing and noted in the data room. A Series B lead who finds expired warrants on the cap table without documentation confirming their termination will ask whether the holder was properly notified and whether any extension or waiver was granted. Silence on the record creates ambiguity that slows diligence.

Continue reading this series:

• The Capital Stack Explained: Equity, Debt, and SAFEs
• How to Value a Startup: Complete Guide for Founders (2026)
• How to Raise Capital for a Startup: Complete Guide to Funding in 2026

IRC Partners works with operators raising $5M to $250M of institutional capital. The full engagement is for founders at $1M+ ARR who have raised before. The $2,997 Capital Raise Pre-Flight audit is open to earlier-stage companies, including pre-revenue, that are raising $5M+ and have a pitch deck and financial model ready for review. If that's you, schedule a call to discuss HERE.